Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucocorticosteroids for primary sclerosing cholangitis.

W Chen1, C Gluud

  • 1Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7102, H:S Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK 2100 Copenhagen, Denmark.

The Cochrane Database of Systematic Reviews
|July 22, 2004
PubMed
Summary

Glucocorticosteroids show no proven benefit for primary sclerosing cholangitis (PSC). Limited trials found no significant improvements in outcomes and noted adverse events, indicating a lack of evidence for their use in PSC.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The risks of adverse events with venlafaxine for adults with major depressive disorder: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis.

Epidemiology and psychiatric sciences·2024
Same author

Tramadol for chronic pain in adults: protocol for a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.

Systematic reviews·2023
Same author

Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

[Glucocorticosteroids for people with alcoholic hepatitis (Cochrane review)].

Terapevticheskii arkhiv·2020
Same author

Ivabradine for coronary artery disease and/or heart failure-a protocol for a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis.

Systematic reviews·2019
Same author

The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2018

Area of Science:

  • Hepatology
  • Gastroenterology
  • Clinical Pharmacology

Background:

  • Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by biliary inflammation and fibrosis.
  • Glucocorticosteroids have been considered as a potential treatment for PSC.

Purpose of the Study:

  • To evaluate the efficacy and safety of glucocorticosteroids in patients with primary sclerosing cholangitis.
  • To assess both beneficial and harmful effects of these agents.

Main Methods:

  • Systematic review and meta-analysis of randomized clinical trials.
  • Searched major databases (Cochrane, MEDLINE, EMBASE) up to March 2003.
  • Included trials comparing glucocorticosteroids with placebo, no intervention, or other immunosuppressants.

Related Experiment Videos

Main Results:

  • Two trials involving 35 patients were included.
  • One trial with hydrocortisone was terminated early due to adverse events and lack of efficacy.
  • Budesonide showed a trend towards better outcomes than prednisone, with significantly lower serum bilirubin levels.

Conclusions:

  • Current evidence does not support the use of oral glucocorticosteroids for primary sclerosing cholangitis.
  • Further research is needed to determine the role of glucocorticosteroids in PSC management.